|
Apr 28, 2021
|
Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies
|
|
|
Mar 25, 2021
|
Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress
|
|
|
Feb 17, 2021
|
Nkarta Announces February and March 2021 Investor Conference Schedule
|
|
